Prof. Jarushka Naidoo, Medical Oncologist, Beaumont Hospital And RCSI University

Bio
Prof. Jarushka Naidoo, MB BCH MHS is a Full Professor of Medical Oncology and Consultant Medical Oncologist at the Beaumont RCSI Cancer Centre in Dublin, Ireland and Adjunct faculty at Johns Hopkins University. She is a clinical trialist and translational researcher with a research interest in non-small cell lung cancer, immunotherapy and immunotherapy-related toxicity. During her time in the USA, Prof Naidoo developed the first institution-wide immunotherapy toxicity multidisciplinary team at Johns Hopkins, and has been a leader in the field of drug toxicity for patients with thoracic malignancies, and specifically immunotherapy. She has authored >100 peer-reviewed papers in thoracic cancer and immune-related toxicity, and led the development of the ASCO, NCCN and SITC immunotherapy toxicity guidelines and drug toxicity taskforces.
Since returning to the Republic of Ireland in 2020, she serves as the Chair of the Lung Cancer Disease-specific subgroup (DSSG) of Cancer Trials Ireland, during which time the clinical trial portfolio for patients with thoracic malignancies has tripled. She also founded and chairs the national lung cancer translational research group called the ‘Irish Lung Cancer Alliance,’ and formed the Irish immunotherapy toxicity network. Prof Naidoo is an active member of ETOP, EORTC, ECOG-ACRIN and NRG clinical trial cooperative groups, and serves on the scientific committees for both ESMO (thoracic cancers), ASCO (immunotherapy) and IASLC (International Association for the Study of Lung Cancer). She is the current chair of the IASLC Communications Committee, and incoming conference chair for IASLC WCLC 2025. She is a prior winner of the IASLC/LCFA Young Investigator Award (2020), and the Irish Cancer Society’s Clinician Research Leader, 2022-2024.